The NCI Community Oncology Research Program (NCORP) is a national network of cancer care investigators, providers, academia, and other organizations that care for diverse populations in health systems.
The DCP Community Oncology and Prevention Trials Research Group administers this program.
On This Page
- All Headings will automatically be pulled in to this list.
- Do not edit the content on this template.
About NCORP
The program brings cancer clinical trials and control and delivery studies to individuals in their own communities, thereby generating a broadly applicable evidence base that contributes to improved patient outcomes and a reduction in cancer disparities.
Grantee Details
No matching Grants were found.
Clinical Trials
| Title | Intervention Sort descending | Sponsor | Status |
|---|---|---|---|
| High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer | Analgesic Agent, Biospecimen Collection, Chemotheraphy, Gabapentin, Placebo, Radiation Therapy, Survey Administration | Alliance for Clinical Trials in Oncology | Recruiting |
| A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) | anastrozole | ECOG-ACRIN Cancer Research Group | Active, not recruiting |
| Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy | Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Olanzapine, Placebo | Alliance for Clinical Trials in Oncology | Completed |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | Anxiety Questionnaire Administration, Quality-of-Life Assessment, Serum Tumor Marker directed disease monitoring, Usual care disease monitoring | SWOG Cancer Research Network | Recruiting |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | Arm 1: Computerized Cognitive Training-Global Stimulation Games, Arm 2: Computerized Cognitive Training-Neuroplasticity Games | NRG Oncology | Recruiting |
| S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases | assessment of therapy complications | SWOG Cancer Research Network | Completed |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | Assessment of Therapy Complications, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration | Children's Oncology Group | Recruiting |
| S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride | assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment | SWOG Cancer Research Network | Completed |
| Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT) | Atorvastatin, Placebo | Wake Forest University Health Sciences | Completed |
| Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome | auranofin, placebo, questionnaire administration | Mayo Clinic | Completed |
Publications
News and Events
AACR Announces 2024 Distinguished Public Service Award Recipients
Date Posted: February 19, 2024
Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up
Date Posted: December 22, 2023
Worta McCaskill-Stevens, M.D.: An Appreciation for a Driving Force in Cancer Prevention and Addressing Cancer Disparities
Date Posted: November 17, 2023
Acting Chief of Community Oncology and Prevention Trials Research Group Named
Date Posted: November 1, 2023
NCORP Director Worta McCaskill-Stevens Honored with Career Development Award in Her Name
Date Posted: August 24, 2023